Here's Why You Should Add Merit Medical Stock to Your Portfolio Now

Merit Medical has growth opportunities from new products, broader procedure exposure and potential WRAPSODY adoption, while its shares are down 1.2% year to date versus gains of 4.7% for its industry and 13.1% for the S&P 500. The article cites approximately $16 million in tariff costs included in the 2026 earnings outlook, alongside reimbursement delays, pricing pressure and China weakness as risks. 2026 consensus EPS remains unchanged at $4.30; third-quarter 2026 revenue is estimated at $410.4 million, up 6.8% year over year, and EPS at $1.04, up 13%.

Analysis

The promotional framing overweights product breadth and clinical evidence; the investable question is whether those assets convert into durable, profitable sales. WRAPSODY’s trial data may support physician interest, but prior recall-related adoption damage makes account reactivation and repeat use the key commercial proof points. Watch procedure-level adoption, renal-therapy growth, and revenue contribution—not launch announcements or physician feedback alone. A slower rebuild would leave the growth narrative dependent on less visible launches and acquisitions, while integration and launch spending could dilute near-term operating leverage.

The tariff burden is partly incorporated into guidance, so the risk is less the known cost than incremental restrictions, poor pass-through, or sourcing disruption that forces estimate cuts. Hospital purchasing power and China pricing pressure could also prevent revenue growth from translating into margin expansion. This is a months-long earnings-quality catalyst, with a 6–18 month opportunity if adoption and new products scale; the immediate setup is not compelling on the article alone. YTD lag is not evidence of undervaluation without valuation and revision context. Treat the Zacks-style growth case skeptically until reported results validate it.

Key Decisions for Investors

• Do not chase MMSI on the promotional thesis. Consider a small, staged long only after the next reported results show WRAPSODY account reactivation translating into sales and gross margin holding despite tariffs; add only if forward estimates begin to rise.
• Keep the position below normal size ahead of the next earnings catalyst. The upside case is estimate expansion from profitable product adoption; the downside is a growth/margin miss that turns a known tariff cost into broader guidance pressure.
• Falsify the long thesis if renal-therapy growth or WRAPSODY adoption stalls, management lowers the outlook, or tariff-related costs exceed planned mitigation. Verify reported tariff exposure, product-level growth, and reimbursement progress before sizing up.
• No relative-value trade in OPK, GMED, or WST is supported by this article: their mentions and estimate statistics do not establish direct product substitution or comparable valuation.